American Society of Hirudotherapy

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy

Narrative review published in The Annals of pharmacotherapy (2004)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical LiteratureHeuts et al. · The Annals of pharmacotherapy, 2004

Abstract

OBJECTIVE: To review current data regarding low-molecular-weight heparin (LMWH) use for perioperative anticoagulation in patients receiving chronic warfarin therapy. DATA SOURCES: Data were obtained from the Sixth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy guidelines and a MEDLINE search (1996-January 2003). Search terms included heparin, low-molecular-weight heparin, warfarin, perioperative care, and anticoagulants. DATA SYNTHESIS: Heparin is the most common agent used as bridge therapy for perioperative anticoagulation in patients on chronic warfarin therapy; LMWHs are also used. Studies that evaluated enoxaparin and/or dalteparin were reviewed. CONCLUSIONS: Although published studies demonstrate efficacy and safety of LMWHs, more data are needed to support their use as bridge therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsClinical Trials as TopicFibrinolytic AgentsHeparin, Low-Molecular-WeightHumansPerioperative CareThromboembolismWarfarin

Summary

This review examines low-molecular-weight heparin as bridge therapy for patients on chronic warfarin during the perioperative period, concluding that published data support LMWH efficacy and safety but that additional studies are needed to confirm these findings.

Context

This review examined current data on low-molecular-weight heparin (LMWH) use for perioperative anticoagulation bridging in patients on chronic warfarin therapy, drawing on ACCP consensus guidelines and a MEDLINE search (1996–2003) covering enoxaparin and dalteparin. It concluded that while published studies demonstrate efficacy and safety of LMWHs, more data are needed to support their use as bridge therapy. The article does not address leeches, hirudotherapy, or leech-derived anticoagulants. This is a conventional heparin/warfarin pharmacology review with no leech secretome content.

Citation

Reference (Vancouver style)

Heuts LM, Arvik BM, Cender DE. LMWH for perioperative anticoagulation in patients on chronic warfarin therapy. Ann Pharmacother. 2004;38(6):1065-1069. doi:10.1345/aph.1D287. PMID: 15113980

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.